Palvella Therapeutics Quarterly Income Statement
NASDAQ: PVLAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
138.77+7.43 (+5.66%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Palvella Therapeutics revenue and earnings
Palvella Therapeutics reported a net loss of $21.9 million, compared with a loss of $9.5 million a year earlier. Diluted earnings per share came in at -$1.52.
Summary generated from market data by MetaCap's automated system. Methodology
Palvella Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | 0 | 0 | 53.00K | 1.30M | 19.52M |
| Revenue growth (YoY) | — | — | — | — | — | — | — | -100.00% | -100.00% | -97.26% | -77.78% | +263.50% |
| Operating Expenses | 21.41M | 14.86M | 11.30M | 10.18M | 9.25M | 7.87M | 4.37M | 5.06M | 2.91M | 1.76M | -54.90M | 31.33M |
| Research & Development | 12.47M | 9.33M | 7.12M | 6.53M | 5.12M | 4.07M | 2.54M | 3.18M | 1.44M | 984.00K | -28.55M | 9.60M |
| Operating Income | -21.41M | -14.86M | -11.30M | -10.18M | -9.25M | -7.87M | -4.37M | -5.06M | -2.91M | -1.76M | 13.39M | -11.81M |
| Interest Expense | — | — | 0 | 0 | 0 | — | 181.00K | 220.00K | 29.00K | — | — | — |
| Other Income (Expense) | -8.00K | -32.00K | -92.00K | 34.00K | 561.00K | 224.00K | -1.00K | -20.00K | 64.00K | 0 | 424.00K | 506.00K |
| Pretax Income | -21.87M | -15.77M | -12.71M | -11.35M | -9.47M | -8.19M | -3.95M | -6.78M | -4.17M | -2.54M | — | — |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — |
| Net Income | -21.87M | -15.77M | -12.71M | -11.35M | -9.47M | -8.19M | -3.95M | -6.78M | -4.17M | -2.54M | 38.65M | -10.75M |
| Net Income growth (YoY) | — | — | — | — | — | — | -110.22% | — | -204.93% | — | — | — |
| EPS (Basic) | -1.52 | -1.20 | -1.08 | -1.03 | -0.86 | -0.74 | 0.12 | -3.94 | -2.47 | -1.54 | 21.41 | -8.70 |
| EPS (Diluted) | -1.52 | -1.20 | -1.08 | -1.03 | -0.86 | -0.74 | 0.12 | -3.94 | -2.47 | -1.54 | — | -8.70 |
| Shares Outstanding (Basic) | 14.36M | 13.09M | — | 11.06M | 11.05M | 11.01M | — | 1.77M | 1.77M | 1.77M | — | 1.24M |
| Shares Outstanding (Diluted) | 14.36M | 13.09M | — | 11.06M | 11.05M | 11.01M | — | 1.77M | 1.77M | 1.77M | — | 1.24M |
| EBITDA | — | — | — | — | — | — | — | -5.06M | -2.91M | -1.79M | 13.19M | -11.07M |
| Operating Margin | — | — | — | — | — | — | — | — | — | -3318.87% | 1030.48% | -60.49% |
| Net Margin | — | — | — | — | — | — | — | — | — | -4784.91% | 2975.37% | -55.08% |
This table shows 12 quarterly periods of Palvella Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow PVLA's reporting calendar. What is a income statement?